Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older.~* Moderate to severe high blood pressure. This is defined as a systolic pressure (the top number) greater than or equal to 160 mmHg and less than 200 mmHg.~Exclusion Criteria:~* History of allergy or hypersensitivity to ARBs, CCBs, thiazide diuretics~* Inability to stop all prior blood pressure medications safely~* Systolic BP ≥ 200 mmHg and/or diastolic BP ≥ 120 mmHg~* Controlled blood pressure (systolic BP \< 140 mmHg) taking more than 3 antihypertensive medications at screening~* Systolic BP ≥ 140 mmHg and \< 180 mmHg taking more than two antihypertensive medications at screening~* Systolic BP ≥ 180 mmHg taking more than one antihypertensive medication at screening~* History of autoimmune diseases~* History of multiple drug allergies~* Liver disease~* Pancreatic injury within 1 year of screening~* Evidence of kidney impairment or history of dialysis~* Any surgical or medical condition which might alter the absorption, distribution, metabolism, or excretion of any drug. This could include currently active gastritis, ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction.~* Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, would be excluded UNLESS they are post-menopausal, surgically sterile OR are using acceptable methods of contraception. The use of hormonal contraceptives is not allowed~* Pregnant or nursing (lactating) women~* History of malignancy of any organ system within the past five years~* Any severe, life-threatening disease within the past five years~* History of drug or alcohol abuse within the last 2 years.~* History of stroke, angioplasty, coronary artery bypass graft surgery, heart attack or unstable angina~* Type 1 diabetes~* Poorly controlled Type 2 diabetes~* History of heart failure~* Arrhythmia~* Significant valvular heart disease~* Active gout~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).